Similar Papers

Paper Title
Journal
Date
Author
Changes of Clonality of Paroxysmal Nocturnal Hemoglobinuria (PNH) Clones during Clinical Courses in Patients with PNH.
Hideyoshi Noji ... Tsutomu Shichishima
Blood | VOL. 110
Hideyoshi Noji, et. al.Hideyoshi Noji ... Tsutomu Shichishima
16 Nov 2007
IMPLICATIONS OF RECENT INSIGHTS INTO THE PATHOPHYSIOLOGY OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
Peter Hillmen ... Stephen J Richards
British Journal of Haematology | VOL. 108
Peter Hillmen, et. al.Peter Hillmen ... Stephen J Richards
01 Mar 2000
The pathophysiology of paroxysmal nocturnal hemoglobinuria
Charles J Parker
Experimental Hematology | VOL. 35
Charles J ParkerCharles J Parker
28 Mar 2007
PIG-a Mutations in a Brazilian Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria
Patricia Eiko Yamakawa ... Celso Arrais-Rodrigues
Blood | VOL. 134
Patricia Eiko Yamakawa, et. al.Patricia Eiko Yamakawa ... Celso Arrais-Rodrigues
13 Nov 2019
View more papers

More From: Journal of Clinical Investigation

Paper Title
Journal
Date
Author
Inhibition of aortic CX3CR1+ macrophages mitigates thoracic aortic aneurysm progression in Marfan syndrome in mice
Jiaqi Huang ... Yi Fu
Journal of Clinical Investigation | VOL. 135
Jiaqi Huang, et. al.Jiaqi Huang ... Yi Fu
16 Jan 2025
FOXO1 pathway activation by VISTA immune checkpoint restrains pulmonary ILC2 functions
Mohammad Hossein Kazemi ... Omid Akbari
Journal of Clinical Investigation | VOL. -
Mohammad Hossein Kazemi, et. al.Mohammad Hossein Kazemi ... Omid Akbari
02 Jan 2025
A conserved human CD4+ T cell subset recognizing the mycobacterial adjuvant, trehalose monomycolate
Yuki Sakai ... Sho Yamasaki
Journal of Clinical Investigation | VOL. -
Yuki Sakai, et. al.Yuki Sakai ... Sho Yamasaki
24 Dec 2024
CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer
Giulia Fracassi ... Francesca Demichelis
Journal of Clinical Investigation | VOL. -
Giulia Fracassi, et. al.Giulia Fracassi ... Francesca Demichelis
24 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.